| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440951 | European Journal of Cancer | 2016 | 8 Pages |
Abstract
Our randomised clinical trial comparing ADC + BSC versus BSC in mCRC demonstrates that ADC generates a tumour-specific immune response but not benefit on PFS and OS. Our results do not support the use of ADC alone, in a phase III trial.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Miguel Caballero-Baños, Daniel Benitez-Ribas, Jaime Tabera, Sara Varea, Ramon Vilana, Luis Bianchi, Juan Ramón Ayuso, Mario Pagés, Gemma Carrera, Miriam Cuatrecasas, Marta Martin-Richard, Joan Cid, Miguel Lozano, Antoni Castells,